Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06177353

Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro — ISTRADEB  

Epidermolysis Bullosa Dystrophica Clinical Trial

Official title:
Etude du Profil Immunologique Sanguin et cutané Des Patients Atteints d'épidermolyse Bulleuse Dystrophique récessive : Analyses in Vivo et Impact Des Cellules Souches Placentaires in Vitro

Clinical Trial Summary

Patients with recessive dystrophic epidermolysis bullosa (RDEB) suffer from acute and chronic post-bullous wounds along with impaired skin healing. These issues are attributed not only to mucocutaneous fragility and abnormal healing directly related to quantitative and/or qualitative constitutional abnormalities of collagen VII but also to a contingent cutaneous and systemic inflammatory component. This inflammatory aspect contributes to the perpetuation of skin lesions and delayed healing. Our primary objective is to define the systemic immunological/inflammatory signature of patients with RDEB with an aim to develop a strategy that involves using stem cells with high immunomodulatory/anti-inflammatory capacity such as allogeneic placental stem cells (WJ-MSCs and trophoblasts).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06177353
Study type Observational
Source Assistance Publique - Hôpitaux de Paris
Contact Emmannuelle Bourrat, Pr
Phone +33142499090
Email emmanuelle.bourrat@aphp.fr
Status Not yet recruiting
Phase
Start date March 1, 2024
Completion date March 1, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01263379 - Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa Phase 1/Phase 2
Completed NCT01716169 - Treatment of Chronic and Non-Chronic Wounds in Patients With Recessive Dystrophic Epidermolysis Bullosa Using Helicoll Collagen Dressings Versus Standard of Care N/A
Completed NCT00951964 - Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate) Phase 2
Recruiting NCT03269474 - Computational Drug Repurposing for All EBS Cases
Recruiting NCT01019148 - Characteristics of Patients With Recessive Dystrophic Epidermolysis Bullosa
Completed NCT03241628 - Proof of Concept Study for a Dressing Glove N/A
Not yet recruiting NCT05390073 - Growth Hormone in EB
Recruiting NCT04213703 - A Pilot Study to Explore the Role of Gut Flora in Epidermolysis Bullosa
Recruiting NCT06007235 - CACIPLIQ20 in Wound Healing in Subjects With Epidermolysis Bullosa N/A
Active, not recruiting NCT05843994 - Artificial Intelligence Patient App for RDEB SCCs
Active, not recruiting NCT05033574 - The State of Sexual Development in Children With Inherited Epidermolysis Bullosa
Completed NCT04908215 - INM-755 (Cannabinol) Cream for Treatment of Epidermolysis Bullosa Phase 2
Terminated NCT00587223 - Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB) Phase 3
Active, not recruiting NCT04171661 - Self-Assembled Skin Substitute for the Treatment of Epidermolysis Bullosa Early Phase 1
Terminated NCT00533572 - Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer N/A
Completed NCT00904163 - Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa N/A
Recruiting NCT03786237 - Rigosertib for RDEB-SCC Phase 1/Phase 2